Skip to main content

Table 2 Assessment schedule summary: control arm

From: A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify management by good and poor response to chemoradiotherapy (TRIGGER): study protocol for a randomised controlled trial

Control arm Registration period Intervention phase Annual follow-up Disease statusg
Visit type Prior to patient entry Registration Randomisation (baseline) Post CRT MDT surgery Surgical follow-up Adjuvant chemotherapy for 24 weeks 12 24 36 60
Timelines   ≤4 weeks prior to CRT During CRT 4–6 weeks post CRT   6–12 weeks post CRT 6 weeks post surgery Toxicity assessed at end of each chemotherapy cycle Months from end of CRT
Informed consenta   X X         
Check eligibility criteria   X X         
Diagnosis, history and clinical assessment   X          
Randomisation    X         
Quality of life   X       X   X  
Chemoradiotherapy    X         
Blood sampleb   X   X   X   X X X  
Baseline MRI X           
Restaging MRIc     X        
Surgery      X       
Surgical morbidityf       X   X    
Pathologyd       X      
Chemotherapy        X end of each cycle     
Toxicity assessment        X end of each cycle X    
Annual follow-up      X    X X X X
Adverse eventse     X X X X end of each cycle     
Concurrent medications   X X X X X X end of each cycle     
  1. CRT pre-operative chemoradiotherapy, MDT multidisciplinary team, MRI magnetic resonance imaging
  2. The X also denotes that Clinical Report Forms (CRFs) need completing
  3. aEligible subjects will be asked to provide written informed consent at registration and before randomisation
  4. bIf patient has consented to additional blood sample collection for research
  5. cThe post-CRT MRI should to be performed within 4–6 weeks (maximum of 10 weeks) from completion of CRT
  6. dResected specimen will be prepared and evaluated using a standardised protocol
  7. eAll adverse events will be recorded from the date the post-CRT MRI scan is performed until 30 days after the last dose of chemotherapy is administered during the intervention phase of the trial
  8. fBoth early (4–6 weeks) and late surgical complications (at 12 months) will be recorded
  9. gDisease status at 5 years (does not require clinic visit): alive without metastatic or recurrent disease, alive with metastatic and/or recurrent disease (date diagnosed), dead (date of death)